AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9063959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg three times daily for 1 week before surgery
Number of subjects: 40
Study 9063959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1715297 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cis‐retinoic acid 0.1%
Number of subjects: 1
Study 1715297 — intervention group
Group type: EXPERIMENTAL
Intervention: all‐trans‐retinoic acid 0.05%
Number of subjects: 1
Study 1715297 — intervention group
Group type: COMPARATOR
Intervention: cream base only
Number of subjects: 1
Study 7039528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CPT)
Number of subjects: 44
Study 7039528 — intervention group
Group type: COMPARATOR
Intervention: No chest physiotherapy (NCPT)
Number of subjects: 44
Study 30477961 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg/day for 2 weeks
Number of subjects: 428
Study 30477961 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg/day for 4 weeks
Number of subjects: 428
Study 30477961 — intervention group
Group type: COMPARATOR
Intervention: Ethambutol for 2 months (Control)
Number of subjects: 428
Study 30477961 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ethambutol)
Number of subjects: 428
Study 28965340 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 8
Study 28965340 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 8
Study 28965340 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study 25361658 — intervention group
Group type: EXPERIMENTAL
Intervention: Underground video game (15 min session)
Number of subjects: 29
Study 25361658 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurement without warm-up)
Number of subjects: 29
Study 25361658 — intervention group
Group type: COMPARATOR
Intervention: Underground video game (used before baseline measurement)
Number of subjects: 29
Study 24325584 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted programme (‐30% of the energy requirements)
Number of subjects: 93
Study 22851947 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with the Sun (LWS) programme
Number of subjects: 1365
Study 22851947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LWS programme)
Number of subjects: 1365
Study 19165563 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (L)
Number of subjects: 40
Study 19165563 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (D)
Number of subjects: 40
Study 17888856 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+NRT (nicotine replacement therapy)
Number of subjects: 181
Study 17888856 — intervention group
Group type: COMPARATOR
Intervention: CBT-only
Number of subjects: 181
Study 17888856 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT+NRT
Number of subjects: 181
Study 10737427 — intervention group
Group type: EXPERIMENTAL
Intervention: SQV‐SGC 1200 mg, NFV 750 mg, SQV‐SGC 800 mg plus NFV 750 mg, all with two NRTIs, and SQV‐SGC 800 mg plus NFV 750 mg alone, all three times daily for 48 weeks
Number of subjects: 157
Study 10737427 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (SQV‐SGC and NFV)
Number of subjects: 157
Study 10737427 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with either single protease inhibitor
Number of subjects: 157
Study 8933488 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% CHO solution (HCHO)
Number of subjects: 12
Study 8933488 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% CHO solution (NCHO)
Number of subjects: 12
Study 8933488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON1)
Number of subjects: 12
Study 8933488 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2% CHO solution (LCHO)
Number of subjects: 12
Study 8933488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON2)
Number of subjects: 12
Study 1425883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day (slow release formulation)
Number of subjects: 0
Study 1425883 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 3904819 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen
Number of subjects: 100
Study 3904819 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine
Number of subjects: 100
Study 29461392 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐mL colloid preload followed by 500‐mL crystalloid coload
Number of subjects: 200
Study 29461392 — intervention group
Group type: COMPARATOR
Intervention: 1000‐mL crystalloid coload
Number of subjects: 200
Study 30132797 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) plus multiple avulsions
Number of subjects: 276
Study 30132797 — intervention group
Group type: COMPARATOR
Intervention: Surgery (saphenofemoral junction ligation, GSV strip to the knee and multiple avulsions)
Number of subjects: 276
Study 27893820 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for three days
Number of subjects: 24
Study 27893820 — intervention group
Group type: COMPARATOR
Intervention: Placebo 500 mg once daily for three days
Number of subjects: 24
Study 24804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL-C
Number of subjects: 9795
Study 24804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline apoA-I
Number of subjects: 9795
Study 24804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HDL-C/apoA-I
Number of subjects: 9795
Study 24804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline HDL-C
Number of subjects: 9795
Study 24804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline HDL-C/apoA-I
Number of subjects: 9795
Study 24804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 1 vs. Quartile 4 of HDL-C
Number of subjects: 9795
Study 24804699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 1 vs. Quartile 4 of HDL-C/apoA-I
Number of subjects: 9795
Study 23189311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 20
Study 23189311 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator attachments
Number of subjects: 20
Study 20153481 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy-making task with perceptual and relational matches
Number of subjects: 3
Study 20153481 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy-making task measuring reaction times
Number of subjects: 3
Study 20153481 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy-making task performance
Number of subjects: 3
Study 18610817 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate intervention for Native Hawaiian women and their families
Number of subjects: 18
Study 18610817 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 18
Study 16236875 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1503
Study 16236875 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 1503
Study 12209673 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed/gemcitabine combination
Number of subjects: 42
Study 12209673 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 42
Study 10617249 — intervention group
Group type: COMPARATOR
Intervention: Continuous 1 mg E2
Number of subjects: 1253
Study 10617249 — intervention group
Group type: COMPARATOR
Intervention: 1 mg E2/30 microg NGM
Number of subjects: 1253
Study 10617249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2/90 microg NGM
Number of subjects: 1253
Study 10617249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E2/180 microg NGM
Number of subjects: 1253
Study 7856897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 7856897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg.kg‐1 followed by 1 mg.kg‐1.h‐1)
Number of subjects: 148
Study 7856897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (doses < 10 mg.kg‐1)
Number of subjects: 148
Study 7856897 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (all doses)
Number of subjects: 148
Study 7856897 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial hematocrit
Number of subjects: 148
Study 2023868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment (3.0 MHz, 1.0 W/cm2 for 5 min)
Number of subjects: 10
Study 2023868 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (massage with gels without ultrasound for 5 min)
Number of subjects: 10
Study 31355692 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive strategy intervention designed to improve planning difficulties
Number of subjects: 60
Study 31355692 — intervention group
Group type: COMPARATOR
Intervention: Usual occupational therapy (Control)
Number of subjects: 60
Study 31355692 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive strategy intervention
Number of subjects: 60
Study 28285536 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted complete mesocolic excision (LCME)
Number of subjects: 78
Study 28285536 — intervention group
Group type: COMPARATOR
Intervention: Open complete mesocolic excision (OCME)
Number of subjects: 78
Study 25545380 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL (zoledronic acid) 5 mg annually for 9 years (Z9)
Number of subjects: 190
Study 25545380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Z6P3) after 6 years of ZOL treatment
Number of subjects: 190
Study 25545380 — intervention group
Group type: EXPERIMENTAL
Intervention: ZOL (Z9)
Number of subjects: 190
Study 25545380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Z6P3)
Number of subjects: 190
Study 23372475 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 725
Study 23372475 — intervention group
Group type: COMPARATOR
Intervention: No active intervention (control)
Number of subjects: 725
Study 21324838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic efficacy instrument
Number of subjects: 634
Study 21324838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic efficacy
Number of subjects: 634
Study 21324838 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers with partners willing to quit
Number of subjects: 634
Study 20061311 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (CC + PST)
Number of subjects: 252
Study 17047101 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL alone
Number of subjects: 55
Study 17047101 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL combined with endoscopy
Number of subjects: 55
Study 17047101 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study 16270636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (certoparin 3000 anti Xa IU) subcutaneously once-daily
Number of subjects: 23078
Study 16270636 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU) subcutaneously three-times daily
Number of subjects: 23078
Study 16270636 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (certoparin)
Number of subjects: 23078
Study 16270636 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 23078
Study 11991461 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC/TMD diagnosis of ID type III
Number of subjects: 69
Study 10220121 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (8‐10 mg/day)
Number of subjects: 168
Study 10220121 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20‐40 mg/day)
Number of subjects: 168
Study 7601298 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymomodulin treatment
Number of subjects: 60
Study 7601298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2215953 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐diopter plastic press‐on Fresnel prisms (n = 18)
Number of subjects: 39
Study 2215953 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 21)
Number of subjects: 39
Study 394268 — intervention group
Group type: EXPERIMENTAL
Intervention: lidamidine hydrochloride (10 mg)
Number of subjects: 30
Study 394268 — intervention group
Group type: EXPERIMENTAL
Intervention: lidamidine hydrochloride (18 mg)
Number of subjects: 30
Study 394268 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 31320504 — intervention group
Group type: EXPERIMENTAL
Intervention: Music medicine (noise-canceling headphone-delivered)
Number of subjects: 0
Study 31320504 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (1-2 mg intravenous)
Number of subjects: 0
Study 28615931 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Number of subjects: 136
Study 28615931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 25238118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefeed abdominal circumference (AC)
Number of subjects: 80
Study 25238118 — intervention group
Group type: COMPARATOR
Intervention: Gastric residual volume (GRV)
Number of subjects: 80
Study 25238118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 23289819 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg for 10 days
Number of subjects: 36
Study 23289819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20678791 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (1 Hz) rTMS applied to the anterior portion of the homologue to Broca's area for 20 min per day for 10 days
Number of subjects: 12
Study 20678791 — intervention group
Group type: COMPARATOR
Intervention: Sham control condition
Number of subjects: 12
Study 17724591 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft (ICBG) either alone or augmented with local bone
Number of subjects: 0
Study 17724591 — intervention group
Group type: COMPARATOR
Intervention: Local bone
Number of subjects: 0
Study 17724591 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft (ICBG)
Number of subjects: 0
Study 16766412 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour nicotine patch
Number of subjects: 20
Study 16766412 — intervention group
Group type: COMPARATOR
Intervention: 16-hour nicotine patch
Number of subjects: 20
Study 15534490 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous CPG 7909 injection
Number of subjects: 0
Study 15534490 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous CPG 7909 injection (second dose)
Number of subjects: 0
Study 15534490 — intervention group
Group type: COMPARATOR
Intervention: Intravenous CPG 7909 injection
Number of subjects: 0
Study 11251475 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate solution
Number of subjects: 20
Study 11251475 — intervention group
Group type: COMPARATOR
Intervention: Lactate solution
Number of subjects: 20
Study 9250117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-fortified prepared meal plan
Number of subjects: 560
Study 9250117 — intervention group
Group type: COMPARATOR
Intervention: Self-selected, mixed-food plan
Number of subjects: 560
Study 9250117 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (compliant participants)
Number of subjects: 560
Study 8296180 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular deep relaxation training (15 min sessions, daily for 6 months)
Number of subjects: 98
Study 8296180 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no relaxation training)
Number of subjects: 98
Study 17165349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg/kg
Number of subjects: 59
Study 17165349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 microg/kg
Number of subjects: 59
Study 17165349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg/kg
Number of subjects: 59
Study 17165349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg
Number of subjects: 59
Study 17165349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 29551350 — intervention group
Group type: EXPERIMENTAL
Intervention: Eberconazole 1% otic solution
Number of subjects: 190
Study 29551350 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% solution
Number of subjects: 190
Study 26560350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 26560350 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 25721322 — intervention group
Group type: EXPERIMENTAL
Intervention: Project EX program
Number of subjects: 1546
Study 25721322 — intervention group
Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 1546
Study 22948946 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular group dietary counselling and menu changes
Number of subjects: 429
Study 22948946 — intervention group
Group type: COMPARATOR
Intervention: Advice on hostel menu only (Control)
Number of subjects: 429
Study 20454958 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly predictable stimulus location
Number of subjects: 0
Study 20454958 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable stimulus location
Number of subjects: 0
Study 20454958 — intervention group
Group type: EXPERIMENTAL
Intervention: Very short saccadic latencies
Number of subjects: 0
Study 20454958 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased saccadic latencies (every 100 ms increase)
Number of subjects: 0
Study 20454958 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulating duration of the stimulus
Number of subjects: 0
Study 18793575 — intervention group
Group type: EXPERIMENTAL
Intervention: Avosentan 50 mg after a high-fat, high-calorie breakfast
Number of subjects: 12
Study 18793575 — intervention group
Group type: COMPARATOR
Intervention: Avosentan 50 mg administered in the fasted state
Number of subjects: 12
Study 15833397 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening/stain removing dentifrice (Regimen B)
Number of subjects: 63
Study 15833397 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening/stain removing dentifrice, tooth polish, tooth polisher and whitening/stain removing mouthwash (Regimen C)
Number of subjects: 63
Study 15833397 — intervention group
Group type: COMPARATOR
Intervention: Standard dentifrice (Regimen A)
Number of subjects: 63
Study 11865128 — intervention group
Group type: EXPERIMENTAL
Intervention: CLON
Number of subjects: 136
Study 11865128 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH
Number of subjects: 136
Study 11865128 — intervention group
Group type: EXPERIMENTAL
Intervention: CLON + MPH
Number of subjects: 136
Study 11865128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 11865128 — intervention group
Group type: EXPERIMENTAL
Intervention: CLON alone
Number of subjects: 136
Study 11865128 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH alone
Number of subjects: 136
Study 10440146 — intervention group
Group type: EXPERIMENTAL
Intervention: Transatrial configuration (shocks delivered between the atrial coil and active can)
Number of subjects: 32
Study 10440146 — intervention group
Group type: COMPARATOR
Intervention: Triad configuration (shocks delivered between the right ventricular coil and an active can in common with the proximal atrial coil)
Number of subjects: 32
Study 10440146 — intervention group
Group type: EXPERIMENTAL
Intervention: Triad configuration
Number of subjects: 32
Study 10440146 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial size as a clinical predictor
Number of subjects: 32
Study 8847714 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory interventions offering different levels of relaxation, control, and self‐efficacy
Number of subjects: 231
Study 8847714 — intervention group
Group type: EXPERIMENTAL
Intervention: Different types of preparatory interventions
Number of subjects: 231
Study 8847714 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions providing more coping elements
Number of subjects: 231
Study 8847714 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style interaction with intervention
Number of subjects: 231
Study 2352762 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) with placebo (saline)
Number of subjects: 11
Study 2352762 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) with naloxone (50 mg)
Number of subjects: 11
Study 103114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of haloperidol and low dose piribedil
Number of subjects: 15
Study 103114 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 15
Study 103114 — intervention group
Group type: COMPARATOR
Intervention: Piribedil alone
Number of subjects: 15
Study 28392165 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib or sunitinib (targeted therapy)
Number of subjects: 47
Study 26835562 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care with Vaccaria segetalis taped to the auricular location specific to lung function in TCM
Number of subjects: 11
Study 26835562 — intervention group
Group type: COMPARATOR
Intervention: Standard Care with Vaccaria segetalis taped to random auricular locations (placebo)
Number of subjects: 11
Study 26835562 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 11
Study 24717399 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation from 16 weeks until delivery
Number of subjects: 675
Study 24717399 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus multivitamins
Number of subjects: 675
Study 24717399 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 675
Study 21810400 — intervention group
Group type: EXPERIMENTAL
Intervention: New cytogenetics classification scheme for patients undergoing HCT
Number of subjects: 821
Study 21810400 — intervention group
Group type: COMPARATOR
Intervention: Existing cytogenetics classifications
Number of subjects: 821
Study 19541299 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment for 2 months before surgery
Number of subjects: 39
Study 19541299 — intervention group
Group type: COMPARATOR
Intervention: Direct surgery without preoperative medical treatment
Number of subjects: 39